Asia-Pacific journal of clinical oncology
-
Asia Pac J Clin Oncol · Sep 2013
Cancer in Australia: Actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012.
The Australian Institute of Health and Welfare (AIHW) is a major national agency established by the Australian government to provide information and statistics on Australia's health and welfare. The AIHW and the Australasian Association of Cancer Registries collaborate every year to provide updated information on cancer occurrences and trends in Australia. ⋯ In the last decade, cancer incidence rates increased in males and stabilized in females, while mortality rates decreased steadily. The overall incidence and mortality rates of cancer for Indigenous Australians were higher than for non-Indigenous Australians.
-
Asia Pac J Clin Oncol · Sep 2013
Randomized Controlled TrialPharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
The objective of this economic evaluation, which was based on patients from two randomized controlled clinical trials (NO16966 and NO16967), was to compare direct medical costs to the Australian health-care system of capecitabine plus oxaliplatin (XELOX) and bolus and/or infusional 5-fluorouracil (5-FU) plus folinic acid combined with oxaliplatin (modified [m] FOLFOX-6) in first-line and second-line treatment of advanced or metastatic colorectal cancer (mCRC). ⋯ The use of XELOX, compared with mFOLFOX-6, for the treatment of mCRC is cost-saving in the Australian government health budget.